Evidence map›Paper›PMID 27257423›Full record

ReviewHepatitis monthly2016

Opioid Drugs in Patients With Liver Disease: A Systematic Review.

Hassan Soleimanpour, Saeid Safari, Kavous Shahsavari Nia, Sarvin Sanaie, Seyed Moayed Alavian

Open access · hybridAbstract readReview
In one paragraph

Review in Hepatitis monthly, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 115 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Analysis of systemic opioid prescribing patterns for dyspnea in opioid-naïve cancer patients: a secondary analysis of a multicenter observational study in Japan.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Observational
  7. Article
  8. Review
  9. Opioid analgesics for sedation-based gastrointestinal endoscopy.World journal of gastrointestinal pharmacology and therapeutics · 2025
    Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Hassan SoleimanpourRoad Traffic Injury Research Center, Tabriz University of Medical Sciences, Tabriz, IR Iran.
Saeid SafariPain Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
Kavous Shahsavari NiaEmergency Medicine Research Team, Tabriz University of Medical Sciences, Tabriz, IR Iran.
Sarvin SanaieTuberculosis and Lung Research Center, Tabriz University of Medical Sciences, Tabriz, IR Iran.
Seyed Moayed AlavianBaqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, IR Iran; Tehran Hepatitis Center, Tehran, IR Iran.
Tabriz University of Medical Sciences · IRIran University of Medical Sciences · IRMiddle East Liver Disease Center · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextThe liver, one of the most important organs of the body, is known to be responsible for several functions. The functional contribution of the liver to the metabolism of carbohydrates, protein, drugs and toxins, fats and cholesterol and many other biological processes are still unknown. Liver disorders are classified into two types: acute and chronic. Different drugs are used in liver diseases to treat and control pain. Most pain relief medications such as opioids are metabolized via the liver; therefore, the adverse reactions of drugs are probably higher for patients with liver disease. The current study aimed to evaluate the effects of opioid drugs on patients with liver disease; therefore, it is necessary to select suitable opioids for such patients. EVIDENCE ACQUISITION: This review was written by referring to research literature including 70 articles and four textbooks published from 1958 to 2015 on various reputable sites. Searches were carried out on the key phrases of narcotic pain relievers (opioids), acute and chronic hepatic failure, opioid adverse drug reactions, drug-induced liver injury (DILI) and other similar keywords. References included a variety of research papers (descriptive and analytical), intervention and review articles.

resultsIn patients with liver disease, administration of opioid analgesics should be observed, accurately. As a general rule, lower doses of drugs should be administered at regular intervals based on the signs of drug accumulation. Secondly, the interactions of opioid drugs with different levels of substrates of the P450 cytochrome enzyme should be considered.

conclusionsPain management in patients with liver dysfunction is always challenging to physicians because of the adverse reactions of drugs, especially opioids. Opioids should be used cautiously since they can cause sedation, constipation and sudden encephalopathy effects. Since the clearance of these drugs in patients with hepatic insufficiency is decreased, the initial dose must be decreased, the intervals between doses should be increased and some patients need to be continuously assessed.

Indexed as

Adverse Drug ReactionsLiver DiseaseOpioids

Identifiers

PMID27257423
PMCPMC4887963
OpenAlexW2277958255

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.